Login Register Cart 0
Generic placeholder image

Recent Advances in Drug Delivery and Formulation

Editor-in-Chief

ISSN (Print): 2667-3878
ISSN (Online): 2667-3886

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Research Article

Formulation Development of Azadirachta indica Extract as Nanosuppository to Improve its Intrarectal Delivery for the Treatment of Malaria

Author(s): Tochukwu Chimdindu Okeke, Chukwuebuka Emmanuel Umeyor*, Ifeanyi Thaddeus Nzekwe, Immaculeta Chikamnele Umeyor, Ngozi Maryann Nebolisa, Emmanuel Maduabuchi Uronnachi, Calistus Dozie Nwakile, Chizoba Austinline Ekweogu, Omoirri Moses Aziakpono and Anthony Amaechi Attama

Volume 16, Issue 3, 2022

Published on: 24 June, 2022

Page: [217 - 233] Pages: 17

DOI: 10.2174/2667387816666220426134156

Price: $65

Abstract

Background: Previous folkloric and experimental reports have demonstrated the antimalarial efficacy of Azadirachta indica (AZA) extracts. However, one of the major challenges facing its application for the clinical treatment of malaria is the design of an acceptable dosage form.

Objective: Consequently, we developed AZA extract-loaded nanostructured lipid carriers (NLC) for the formulation of suppositories, denoted as nanosuppositories, for intrarectal treatment of malaria.

Methods: Various batches of NLC-bearing AZA extract were formulated based on lipid matrices prepared using graded concentrations of Softisan®154 and Tetracarpidium conophorum or walnut oil. NLC was investigated by size and differential scanning calorimetry (DSC). Suppository bearing AZA extract-loaded NLC was developed using cocoa butter or theobroma oil, and their physicochemical properties were profiled. In vitro drug release and in vivo antimalarial activity (using Plasmodium berghei-infected mice) were investigated.

Results: NLCs exhibited sizes in nanometers ranging from 329.5 - 806.0 nm, and were amorphized as shown by DSC thermograms. Nanosuppositories were torpedo- or bullet- shaped, weighing 138 - 368 mg, softened/liquefied between 4.10 - 6.92 min, and had controlled release behaviour. In vivo antimalarial study revealed excellent antimalarial efficacy of the nanosuppositories comparable with a commercial brand (Plasmotrim®) and better than the placebo (unloaded nanosuppository), and without toxic alterations of hepatic and renal biochemical factors.

Conclusion: Thus, AZA extract could be rationally loaded in nanostructured lipid carriers (NLC) for further development as nanosuppository and deployed as an effective alternative with optimum convenience for intrarectal treatment of malaria.

Keywords: Azadirachta indica, Tetracarpidium conophorum, malaria, Plasmodium falciparum, nanostructured lipid carriers, nanosuppositories.

« Previous Next »
Graphical Abstract

[1]
World Health Organization. Malaria: Key facts. 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/malaria (Accessed on: 5 August, 2021).
[2]
Etman M, Amin M, Nada AH, Shams-Eldin M, Salama O. Emulsions and rectal formulations containing myrrh essential oil for better patient compliance. Drug Discov Ther 2011; 5(3): 150-6.
[http://dx.doi.org/10.5582/ddt.2011.v5.3.150] [PMID: 22466245]
[3]
Thera MA, Keita F, Sissoko MS, et al. Acceptability and efficacy of intra-rectal quinine alkaloids as a pre-transfer treatment of non-per os malaria in peripheral health care facilities in Mopti, Mali. Malar J 2007; 6: 68.
[http://dx.doi.org/10.1186/1475-2875-6-68] [PMID: 17519031]
[4]
Onyeji CO, Adebayo AS, Babalola CP. Effects of absorption enhancers in chloroquine suppository formulation 1: In vitro release characteristics. Eur J Pharm Sci 1999; 9(2): 131-6.
[5]
Akala EO, Adedoyin A, Ogunbona FA. Suppository formulations of amodiaquine: In vitro release characteristics. Drug Dev Ind Pharm 1991; 17: 303-7.
[http://dx.doi.org/10.3109/03639049109043827]
[6]
Oladimeji FA, Omoruyi SI, Onyeji CO. Preparation and in vitro evaluation of suppositories of halofantrine hydrochloride. Afr J Biotechnol 2006; 5(19): 1775-80.
[7]
Koopmans R, Duc DD, Kager PA, et al. The pharmacokinetics of artemisinin suppositories in Vietnamese patients with malaria. Trans R Soc Trop Med Hyg 1998; 92(4): 434-6.
[http://dx.doi.org/10.1016/S0035-9203(98)91082-3] [PMID: 9850402]
[8]
Karunajeewa HA, Reeder J, Lorry K, et al. Artesunate suppositories versus intramuscular artemether for treatment of severe malaria in children in Papua New Guinea. Antimicrob Agents Chemother 2006; 50(3): 968-74.
[http://dx.doi.org/10.1128/AAC.50.3.968-974.2006] [PMID: 16495259]
[9]
Simba DO, Warsame M, Kimbute O, et al. Factors influencing adherence to referral advice following pre-referral treatment with artesunate suppositories in children in rural Tanzania. Trop Med Int Health 2009; 14(7): 775-83.
[http://dx.doi.org/10.1111/j.1365-3156.2009.02299.x] [PMID: 19497077]
[10]
Umeyor IC, Umeyor CE, Ogbue CO, Onyegbule FA, Okoye FBC. Evaluation of the organ microscopy, chemical composition and anti-inflammatory potentials of methanolic leaf extract and fractions of Diaphananthe bidens. Asian Plant Res J 2021; 8(1): 16-28. a
[http://dx.doi.org/10.9734/aprj/2021/v8i130166]
[11]
Islas JF, Acosta E, Buentello ZG, et al. An overview of neem (Azadirachta indica) and its potential impact on health. J Funct Foods 2020; 74: 104171.
[http://dx.doi.org/10.1016/j.jff.2020.104171]
[12]
Habluetzel A, Pinto B, Tapanelli S, et al. Effects of Azadirachta indica seed kernel extracts on early erythrocytic schizogony of Plasmodium berghei and pro-inflammatory response in inbred mice. Malar J 2019; 18(1): 35.
[http://dx.doi.org/10.1186/s12936-019-2671-8] [PMID: 30736813]
[13]
Bedri S, Khalil EA, Khalid SA, et al. Azadirachta indica ethanolic extract protects neurons from apoptosis and mitigates brain swelling in experimental cerebral malaria. Malar J 2013; 12: 298.
[http://dx.doi.org/10.1186/1475-2875-12-298] [PMID: 23984986]
[14]
Guo T, Zhang Y, Zhao J, Zhu C, Feng N. Nanostructured lipid carriers for percutaneous administration of alkaloids isolated from Aconitum sinomontanum. J Nanobiotechnology 2015; 13: 47.
[http://dx.doi.org/10.1186/s12951-015-0107-3] [PMID: 26156035]
[15]
Umeyor CE, Okoye I, Uronnachi E, Okeke T, Kenechukwu F, Attama A. Repositioning miconazole nitrate for malaria: Formulation of sustained release nanostructured lipid carriers, structure characterization and in vivo antimalarial evaluation. J Drug Deliv Sci Technol 2021; 61: 102125.
[http://dx.doi.org/10.1016/j.jddst.2020.102125]
[16]
Pinheiro M, Ribeiro R, Vieira A, Andrade F, Reis S. Design of a nanostructured lipid carrier intended to improve the treatment of tuberculosis. Drug Des Devel Ther 2016; 10: 2467-75.
[http://dx.doi.org/10.2147/DDDT.S104395] [PMID: 27536067]
[17]
Agbo CP, Ugwuanyi TC, Ugwuoke WI, McConville C, Attama AA, Ofokansi KC. Intranasal artesunate-loaded nanostructured lipid carriers: A convenient alternative to parenteral formulations for the treatment of severe and cerebral malaria. J Control Release 2021; 334: 224-36.
[http://dx.doi.org/10.1016/j.jconrel.2021.04.020] [PMID: 33894303]
[18]
Li X, Vogt FG, Hayes D Jr, Mansour HM. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery. Eur J Pharm Sci 2014; 52: 191-205.
[http://dx.doi.org/10.1016/j.ejps.2013.10.016] [PMID: 24215736]
[19]
Hosseini S, Epple M. Suppositories with bioactive calcium phosphate nanoparticles for intestinal transfection and gene silencing. Nano Select 2021; 2: 561-72.
[http://dx.doi.org/10.1002/nano.202000150]
[20]
British Pharmacopoeia. British Pharmacopoeia Office: MHRA, 151 Buckingham Palace Road, London SW1W9SZ. 2013.
[21]
Saeed AMH, Alaayedi MH, Alshohani ADH. New combination suppositories of lornoxicam and aloin for rheumatoid arthritis. Asian J Pharm Clin Res 2018; 11(2): 308-12.
[http://dx.doi.org/10.22159/ajpcr.2018.v11i2.22921]
[22]
Ribeiro AP, Masuchi MH, Miyasaki EK, et al. Crystallization modifiers in lipid systems. J Food Sci Technol 2015; 52(7): 3925-46.
[http://dx.doi.org/10.1007/s13197-014-1587-0] [PMID: 26139862]
[23]
Kweyamba PA, Zofou D, Efange N, Assob JN, Kitau J, Nyindo M. In vitro and in vivo studies on anti-malarial activity of Commiphora africana and Dichrostachys cinerea used by the Maasai in Arusha region, Tanzania. Malar J 2019; 18(1): 119.
[http://dx.doi.org/10.1186/s12936-019-2752-8] [PMID: 30947717]
[24]
Umeyor C, Attama A, Kenechukwu F, Gugu T, Ugochukwu J. Surface modified self-nanoemulsifying formulations (SNEFs) for oral delivery of gentamicin: In vivo toxicological and pre-clinical chemistry evaluations. Curr Nanomed 2017; 7(3): 237-51.
[http://dx.doi.org/10.2174/2468187307666170512124452]
[25]
Umeyor CE, Obachie O, Chukwuka R, Attama A. Development insights of surface modified lipid nanoemulsions of dihydroartemisinin for malaria chemotherapy: Characterization, and in vivo antimalarial evaluation. Recent Pat Biotechnol 2019; 13(2): 149-65.
[http://dx.doi.org/10.2174/1872208313666181204095314] [PMID: 30514197]
[26]
Havaldar VD, Yadav AV, Dias RJ, Mali KK. Ghorpade, Salunkhe NH. Rectal suppository as an effective alternative for oral administration. Res J Pharm Tech 2015; 8(6): 759-66.
[http://dx.doi.org/10.5958/0974-360X.2015.00122.5]
[27]
Lalani J, Baradia D, Lalani R, Misra A. Brain targeted intranasal delivery of tramadol: Comparative study of microemulsion and nanoemulsion. Pharm Dev Technol 2015; 20(8): 992-1001.
[http://dx.doi.org/10.3109/10837450.2014.959177] [PMID: 25228122]
[28]
Agbo C, Umeyor C, Kenechukwu F, et al. Formulation design, in vitro characterizations and anti-malarial investigations of artemether and lumefantrine-entrapped solid lipid microparticles. Drug Dev Ind Pharm 2016; 42(10): 1708-21.
[http://dx.doi.org/10.3109/03639045.2016.1171331] [PMID: 27095388]
[29]
Glatter O, Gruber K. Indirect transformation in reciprocal space: Desmearing of small-angle scattering data from partially ordered systems. J Appl Cryst 1993; 26: 512-8.
[http://dx.doi.org/10.1107/S0021889893000561]
[30]
Mosbah AE, Mokhtar E. Formulation and evaluation of ibuprofen suppositories. Int Res J Pharm 2016; 7(6): 87-90.
[http://dx.doi.org/10.7897/2230-8407.07670]
[31]
Nnamani PO, Ugwu AA, Ibezim EC, et al. Sustained-release liquisolid compact tablets containing artemether-lumefantrine as alternate-day regimen for malaria treatment to improve patient compliance. Int J Nanomedicine 2016; 11: 6365-78.
[http://dx.doi.org/10.2147/IJN.S92755] [PMID: 27932882]
[32]
Mandawgade SD, Sharma S, Pathak S, Patravale VB. Development of SMEDDS using natural lipophile: Application to beta-Artemether delivery. Int J Pharm 2008; 362(1-2): 179-83.
[http://dx.doi.org/10.1016/j.ijpharm.2008.06.021] [PMID: 18652886]
[33]
Adeyemi OS, Adewumi I. Biochemical evaluation of silver nanoparticles in wistar rats. Int Sch Res Notices 2014; 2014: 196091.
[http://dx.doi.org/10.1155/2014/196091] [PMID: 27350993]
[34]
Daisy P, Saipriya K. Biochemical analysis of Cassia fistula aqueous extract and phytochemically synthesized gold nanoparticles as hypoglycemic treatment for diabetes mellitus. Int J Nanomedicine 2012; 7: 1189-202.
[http://dx.doi.org/10.2147/IJN.S26650] [PMID: 22419867]

Rights & Permissions Print Cite
Article Metrics
3
© 2024 Bentham Science Publishers | Privacy Policy